This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Radiofrequency ablation (RFA) and microwave ablation (MWA) have been proven to be safe and effective methods for treating early-stage hepatocellular carcinoma (HCC). Although researchers have compared the efficacy of MWA and RFA, the results have not been consistent. Therefore, this study utilizes a large sample size and employs propensity score matching (PSM) combined with inverse probability weighting (IPW) to further investigate the effects between the two treatments. METHODS: Patients with early-stage HCC who were diagnosed and treated with MWA or RFA between 2015 and 2022 were collected. The post-treatment effects and tumor outcomes were analyzed using PSM and IPW. RESULTS: The 1-, 2- and 3-year recurrence rates were 40.89%, 68.07% and 84.13% for MWA, and 39.13%, 62.64% and 75.71% for RFA. The overall survival rates at 1, 2 and 3 years were 70.47%, 40.98% and 21.90% for MWA, and 70.53%, 44.85% and 30.60% for RFA. Cox regression indicated that age, tumor number and post-treatment were adverse prognostic factors for recurrence-free survival, while treatment method, age, tumor number and post-treatment were adverse prognostic factors for overall survival. CONCLUSION: The 5-year overall survival rates for RFA and MWA remained similar. The discrepancies in the 5-year cumulative recurrence-free rate might be attributed to the small MWA cohort, possible differences in patient selection, the margin assessment procedure used and the overall short follow-up period.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: